Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Arexvy®, a recombinant respiratory syncytial virus (RSV) pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by RSV, has been available for use in adults aged ≥60 years in Australia on the private market since February 2024, outside the government-funded National Immunisation Program (NIP) and requiring out-of-pocket purchase. A Phase 3 clinical trial of Arexvy conducted in 17 countries reported mostly mild-to-moderate adverse events within 30 days of vaccination, most commonly pain at injection site (60·9%), fatigue (33·6%), myalgia (28·9%) and headache (27·2%).